Review of Ophthalmology Online


#########
Volume 18, Number 26
Monday, June 25, 2018
#########


JUNE IS HEALTHY VISION MONTH



In this issue: (click heading to view article)
#########
######### Retinal Volume as OCT Biomarker for Disease Activity in nAMD
#########
######### Optic Disc Vessel Density in Nonglaucomatous & Glaucomatous Eyes
#########
######### Evaluation of Multispectral Imaging in Diagnosing Diabetic Retinopathy
#########
######### Macular & ONH Vessel Density and Progressive RNFL Loss in Glaucoma
#########
  Briefly

 

Retinal Volume as OCT Biomarker for Disease Activity in nAMD

Researchers wrote that current algorithms for automated computer interpretation of optical coherence tomography imaging of individuals with neovascular age-related macular degeneration mainly rely on fluid detection. However, correct interpretation of the fluid currently limits diagnostic accuracy, they added. Therefore, researchers performed a detailed analysis of requirements that would have to be met to validate fluid detection approaches. They further investigated if monitoring retinal volume would be a viable alternative to detect disease activity.

The study included retrospective analysis and manual grading of 764 OCT volume scans of 44 individuals with exudative AMD treated with intravitreal anti-VEGF injections as part of a pro re nata treatment regimen for at least 24 months and reported their findings.

• Detection of subretinal fluid or intraretinal fluid alone wasn’t sufficient for disease detection. Researchers suggested that combining these findings with SRF and IRF could detect disease activity with a sensitivity of 98.6 percent and a specificity of 82 percent and that, with further characterization of IRF into exudative and degenerative cysts, specificity could be increased to 100 percent. They added that correct characterization is currently not achieved by published fluid detection approaches.
• Changes in macular retinal volume could reveal disease activity with sensitivity of 88.4 percent and specificity of 89.6 percent. Researchers found that combining this measurement SRF with detection could improve diagnostic accuracy to a specificity of 93.3 percent and sensitivity of 93.9 percent without relying on IRF or IRF characterization.

Researchers determined that fluid detection without further characterization wasn’t sufficient for AMD monitoring. They wrote that either additional distinctions between exudative and degenerative cysts would be necessary for monitoring or other activity markers would have to be taken into account. Researchers concluded that MRV offered the potential to fill this diagnostic gap and might become an important monitoring marker.

SOURCE: von der Burchard C, Treumer F, Ehlken C, et al. Retinal volume change is a reliable OCT biomarker for disease activity in neovascular AMD. Graefes Arch Clin Exp Ophthalmol 2018; June 18. [Epub ahead of print].





Optic Disc Vessel Density in Nonglaucomatous & Glaucomatous Eyes

Investigators evaluated the ability of enhanced-depth imaging optical coherence tomography angiography to detect vascular signals inside the glaucomatous optic disc.

Ten glaucomatous eyes of eight subjects, and 11 nonglaucomatous eyes of seven subjects underwent EDI and conventional OCTA for optic disc analysis. Investigators compared the optic disc vessel density at maximum scan depths (2 mm) between the two methods and between glaucomatous and nonglaucomatous eyes. They used regression analysis to determine factors affecting disc VD.

• The median (25th, 75th percentile) of the visual field MD was -20.5 (-25.1, -13.5) dB in glaucoma.
• Disc VD measured with the EDI method was significantly greater with the conventional method in glaucoma and nonglaucoma.
• Disc VD was significantly lower in glaucoma than in nonglaucoma.
• Disc VD and mean deviation were significantly and positively correlated in both methods (conventional: R2=0.27, EDI: R2=0.22).

Investigators reported that the correlation between disc VD and glaucoma severity was comparable between conventional and EDI measurements. Images obtained with EDI-OCTA had the additional benefit of revealing more vascular signals in deeper layers, they added. Furthermore, they suggested that the disc VD, as determined by conventional and EDI-OCTA methods, might be an indicator of glaucoma severity.

SOURCE: Yoshikawa Y, Shoji T, Kanno J, et al. Optic disc vessel density in nonglaucomatous and glaucomatous eyes: An enhanced-depth imaging optical coherence tomography angiography study. Clin Ophthalmol 2018;12:1113-9.



Evaluation of Multispectral Imaging in Diagnosing Diabetic Retinopathy

Scientists assessed multispectral imaging as a novel diagnostic approach for diabetic retinopathy in clinical settings.

A total of 50 type 2 diabetic patients (99 eyes) were enrolled in this cross-sectional study. All subjects underwent digital fundus photography, MSI and fundus fluorescein angiography. Scientists calculated total exact agreement, sensitivity, specificity, positive predictive value and negative predictive value of no DR/mild nonproliferative DR and severe NPDR/proliferative DR grading based on DFP and MSI, and compared the findings with fundus fluorescein angiography.

Compared with fundus fluorescein angiography:
• the exact agreement for MSI was 0.835; for DFP it was 0.614;
• the sensitivity for no DR/mild NPDR in MSI and DFP was 100 percent, and for severe NPDR/PDR it was 97.4 percent and 88.3 percent.
• The specificity for no DR/mild NPDR in MSI and DFP was 96.3 percent and 95 percent, and for severe NPDR/PDR it was 100 percent in both.
• The positive predictive value for no DR/mild NPDR in MSI and DFP was 86.4 percent and 82.6 percent, and for severe NPDR/PDR it was 100 percent in both.
• The negative predictive value for no DR/mild NPDR in MSI and DFP was 100 percent, and for severe NPDR/PDR it was 91.7 percent and 71 percent in both.

Scientists found that multispectral imaging displayed excellent agreement with fundus fluorescein angiography in DR grading, suggesting it might serve as a new diagnostic technique for evaluating DR.

Li L, Zhang P, Liu H, et al. Evaluation of multispectral imaging in diagnosing diabetic retinopathy. Retina 2018; Jun 12. [Epub ahead of print].




Macular & ONH Vessel Density and Progressive RNFL Loss in Glaucoma

Researchers investigated the relationship between macular and peripapillary vessel density and progressive retinal nerve fiber layer loss in individuals with mild to moderate primary open-angle glaucoma, as part of a prospective, observational study. They included 132 eyes of 83 individuals with glaucoma followed for at least two years (average: 27.3 ±3.36 months).

Researchers acquired measurements of macular whole-image vessel density (m-wiVD) and optic nerve head whole-image vessel density (onh-wiVD) at baseline using optical coherence tomography angiography. RNFL, minimum rim width and ganglion cell plus inner plexiform layer thickness were obtained semiannually using spectral-domain OCT. Researchers used random effects models to evaluate the relationship between baseline vessel density parameters and rates of RNFL loss after adjusting for the following confounding factors:
• baseline visual field mean deviation;
• MRW;
• GCIPL thickness;
• central corneal thickness; and
• mean intraocular pressure during follow-up and disc hemorrhage, with or without including baseline RNFL.
The main outcome measures included effects of m-wiVD and onh-wiVD on rates of RNFL loss over time.

The average baseline RNFL thickness was 79.5 ±14.8 μm, which declined with a mean slope of -1.07 μm/year (CI, -1.28 to -0.85). In the univariate model— including only a predictive factor and time, and interactions—each 1 percent lower m-wiVD was associated with a 0.11 μm/year (p<0.001) faster rate of RNFL decline, and each 1 percent lower onh-wiVD was associated with a 0.06 μm/year (p=0.031) faster rate of RNFL decline. A similar relationship between low m-wiVD and onh-wiVD, and faster rates of RNFL loss was found using different multivariate models. The association between vessel density measurements and rate of RNFL loss was weak (r2=0.125 for m-wiVD and and r2=0.033 for onh-wiVD). Average CCT also was a predictor for faster RNFL decline in univariate (0.11 μm/year; p<0.001) and multivariate models.

Researchers concluded that lower baseline macular and optic nerve head vessel densities were associated with a faster rate of RNFL progression in mild to moderate glaucoma. They suggested that assessment of ONH and macular vessel density might add significant information to the evaluation of glaucoma risk and prediction of worsening disease.

Moghimi S, Zangwill LM, Penteado RC, et al. Macular and optic nerve head vessel density and progressive retinal nerve fiber layer loss in glaucoma. Ophthalmology 2018; Jun 12. [Epub ahead of print].





  • B+L Receives FDA Pre-Market Approval For Envista Toric MX60T IOL
    Bausch + Lomb received FDA pre-market approval for the enVista toric MX60T, the company’s first hydrophobic acrylic intraocular lens for astigmatism correction. The IOL features a one-piece, aberration-free, aspheric optic with fenestrated, step-vaulted, modified C-loop haptic design intended to deliver rotational stability and predictable astigmatism correction, the company says. Additionally, the optic’s posterior square edge is designed to provide a 360-degree barrier to posterior capsular opacification. Read more.



  • Optovue Expands FDA Clearance of Epithelial Thickness Mapping
    Optovue received expanded FDA 510(k) clearance for non-contact, quantitative measurements of the epithelial and stromal layers of the cornea, i.e., epithelial thickness mapping. The expanded clearance adds a 9 mm ETM scan to the previously available 6-mm map. The company says that its ETM, now available on the Avanti Widefield OCT system, is the first FDA-cleared product indicated to provide corneal epithelial and stromal measurements that aid in the diagnosis, documentation and management of ocular health and diseases in the adult population. ETM was previously cleared on the company’s iVue system in 2017. Read more.



  • Reichert Introduces Phoroptor VRx Virtual Live Demo Experience
    Reichert Technologies introduced the Phoroptor VRx Virtual Live Demo Experience enabling a Reichert specialist to conduct a demonstration of the digital refraction system via a live, one-on-one video conferencing feed. Through the technology, the company can demonstrate all system components, including the head and controller, and the ClearChart 4 Digital Acuity System. Learn more.



  • Avedro Enrolls First Patient in Phase III Epi-on Corneal Cross-linking Trial for Progressive Keratoconus
    Avedro began enrolling patients in a Phase III clinical trial to evaluate the safety and efficacy of an epithelium-on corneal collagen cross-linking procedure to treat patients with progressive keratoconus. The multicenter, randomized, controlled trial of a novel corneal cross-linking procedure involves 275 individuals with progressive keratoconus across approximately 20 sites in the United States. Read more.




Review of Ophthalmology® Online is published by the Review Group, a Division of Jobson Medical Information LLC (JMI), 11 Campus Boulevard, Newtown Square, PA 19073.

To subscribe to other JMI newsletters or to manage your subscription, click here.

To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address.

To ensure delivery, please be sure to add reviewophth@jobsonmail.com to your address book or safe senders list.

Click here if you do not want to receive future emails from Review of Ophthalmology Online.

Advertising: For information on advertising in this e-mail newsletter or other creative advertising opportunities with Review of Ophthalmology, please contact sales managers James Henne or Michele Barrett.

News: To submit news or contact the editor, send an e-mail, or FAX your news to 610.492.1049